Introduction: Biotech Is Venture Capital at Its Most Difficult and Most Important
Biotech is not a normal startup category.
A software company can launch a product, measure user behavior, improve weekly, and pivot if the market does not respond.
A biotech company cannot move that way.
A biotech startup may spend years before treating a patient.
It may spend millions before meaningful clinical evidence exists.
It may need specialized labs, animal studies, chemistry, manufacturing, toxicology, regulatory strategy, clinical trial design, patient recruitment, manufacturing controls, intellectual property protection, pharma partnerships, and a management team that understands science and markets.
Failure is common.
Timelines are long.
Capital needs are high.
The consequences are real.
A biotech startup is not only selling convenience or productivity. It is trying to change disease biology, improve survival, reduce suffering, extend life, or create a therapeutic option where none exists.
That is why biotech venture capital is so different from ordinary startup investing.
It is also why McKinsey’s article “What early-stage investing reveals about biotech innovation” matters.
The article was published in December 2023, when public biotech markets were still struggling after the 2021 boom. IPO activity had fallen sharply, biotech stock valuations had dropped, and many public companies had cut staff or narrowed pipelines to preserve cash.
But the early-stage market told a different story.
Venture capital had cooled from the 2021 peak, but it had not disappeared. More importantly, investors continued to fund innovative platform companies, especially machine-learning-enabled drug discovery, cell therapies, gene therapies, and oligonucleotide therapies.
That tells us something important:
Public markets may be afraid of biotech risk, but early-stage investors still believe the science is moving.
The public market asks, “Where is the revenue?”
The venture market asks, “What could this science become if the next risk is reduced?”
Those are different questions.
Biotech exists between them.
This article explains what early-stage investing reveals about where biotech innovation is going, why platforms matter, why AI is both powerful and overhyped, why cell and gene therapies remain central, how founders should think about milestones, and what this means for biotech ecosystems in the USA and Canada.
1. Biotech Public Markets Struggled, but Venture Capital Kept Looking Forward
McKinsey’s article begins with a contradiction.
Public biotech markets were weak, but private biotech innovation remained active.
That matters because biotech capital markets often move in cycles.
In hot public markets, biotech IPOs become easier. Companies can go public earlier, raise larger rounds, and access public investors before late-stage clinical proof. Venture investors can recycle capital through IPOs. Founders have more financing options.
In weak public markets, the opposite happens.
IPO windows close.
Public valuations fall.
Crossover investors become cautious.
Biotechs cut pipelines.
Layoffs rise.
Companies conserve cash.
Private companies stay private longer.
Venture investors become more selective.
The post-2021 biotech downturn forced the sector to become more disciplined. Public investors were no longer willing to fund every platform story. They wanted better evidence, clearer pipelines, stronger balance sheets, and more credible paths to value.
But venture investors did not abandon biotech.
They continued funding early-stage companies because the scientific opportunity remained large.
This is one of biotech’s unique features.
The stock market can be pessimistic while the science keeps advancing.
A public biotech index can fall while new modalities improve.
IPO markets can close while labs generate better tools.
Layoffs can happen while AI models, gene editing, cell engineering, and RNA therapeutics continue developing.
Founders need to understand this distinction.
A bad public market does not mean the science is bad.
But it does mean the financing path is harder.
2. Early-Stage Investing Reveals What Investors Believe the Future Could Become
Early-stage venture capital is a belief market.
Investors are not only funding what is true today. They are funding what could become true if the science works.
In biotech, early-stage investing reveals where investors believe major therapeutic progress may come from.
McKinsey’s data showed that platform companies dominated venture funding in 2022. These included machine-learning-enabled drug discovery companies, cell therapies, and gene and oligonucleotide therapies.
This is important because platform companies are different from single-asset companies.
A single-asset biotech may be built around one molecule, one target, one indication, or one lead program.
A platform biotech claims something broader:
A discovery engine.
A modality.
A manufacturing approach.
A targeting system.
A cell-engineering method.
A gene-editing toolkit.
An RNA platform.
A computational system.
A biological logic platform.
If the platform works, it can produce multiple drugs.
That is the attraction.
A successful platform can create a pipeline, not just a product.
It can generate several shots on goal.
It can partner with pharma across indications.
It can become an acquisition target.
It can build internal programs and external collaborations.
It can create a company with multiple ways to win.
But platforms are also risky.
They can become vague.
They can absorb huge capital before producing clinical proof.
They can overpromise.
They can struggle to choose which asset to move forward.
They can become science projects rather than drug companies.
The investor’s job is to ask:
Is this truly a platform, or just a technology story?
Can it produce drug candidates?
Can it select indications intelligently?
Can it generate data that reduces risk?
Can it scale scientifically and operationally?
Can it create differentiated assets?
Can it eventually prove patient benefit?
A biotech platform is valuable only if it leads to medicines.
3. Platform Biotech Is Attractive Because It Offers Multiple Shots on Goal
The appeal of a biotech platform is easy to understand.
Drug development is risky. Many programs fail. If a company depends entirely on one program, the company can collapse when that program fails.
A platform offers a different logic.
If the underlying technology can generate multiple programs, the company may have more chances to succeed.
This is why venture investors often like platforms.
A machine-learning drug-discovery platform may discover multiple molecules.
A cell-therapy platform may be adapted to multiple cancers or immune diseases.
A gene-editing platform may target multiple genetic disorders.
An RNA platform may affect several disease pathways.
A delivery platform may enable many therapeutic payloads.
But founders must be careful.
“Multiple shots on goal” can become an excuse for lack of focus.
A platform company still needs a lead program.
It still needs a development strategy.
It still needs proof points.
It still needs to select indications where the platform advantage matters.
It still needs a path to clinical data.
It still needs to show investors why the platform creates better assets than traditional approaches.
The best platform companies combine breadth and focus.
Breadth creates the long-term company.
Focus creates the next financing round.
A founder should be able to say:
Here is the platform.
Here is why it is different.
Here is the first program.
Here is why this program proves the platform.
Here is the next milestone.
Here is how that milestone changes the company’s value.
Without that logic, the platform story becomes too abstract.
4. AI Drug Discovery Is One of the Biggest Questions in Biotech
McKinsey identifies machine-learning-enabled drug discovery as one of the dominant platform areas attracting venture funding.
This is not surprising.
Drug discovery is expensive, slow, and failure-prone. The idea that AI could improve target discovery, molecule design, protein interaction prediction, patient selection, trial design, or translational biology is deeply attractive.
AI could help biotech in many ways:
Integrating large omics datasets.
Identifying disease mechanisms.
Selecting better targets.
Designing molecules.
Predicting protein structures and interactions.
Improving computational chemistry.
Analyzing microscopy and imaging.
Finding biomarkers.
Matching patients to therapies.
Optimizing clinical trial design.
Reducing failed experiments.
Improving manufacturing processes.
Generating scientific hypotheses.
But AI in biotech is not the same as AI in consumer software.
The ultimate test is not whether the model produces a convincing answer.
The test is whether the answer survives biology.
Biology is messy.
Human disease is complex.
Datasets are incomplete.
Clinical translation is difficult.
Preclinical success often fails in humans.
The body is not a software environment.
That is why AI drug discovery remains both exciting and unproven at scale.
The key investor questions are:
Does AI improve probability of success?
Does it reduce time?
Does it reduce cost?
Does it generate better molecules?
Does it identify better targets?
Does it improve patient selection?
Does it produce assets that succeed clinically?
Does the company own unique data?
Does the model improve with experimental feedback?
Does the company have wet-lab validation?
Does it have enough biology depth, or only computation?
The winners in AI biotech will not be the companies with the best pitch about algorithms.
They will be the companies that turn computation into better therapeutic decisions.
5. The Real AI Biotech Moat Is Not the Model Alone
In the early AI boom, many founders assumed the model was the moat.
That is becoming less true.
Foundation models improve.
Open-source tools improve.
Computing access changes.
Large pharma builds internal AI teams.
Cloud providers offer life-sciences AI infrastructure.
Academic models become more powerful.
If the model alone is not enough, where does the moat come from?
In biotech AI, defensibility may come from:
Unique biological datasets.
High-quality experimental feedback loops.
Proprietary assays.
Integrated wet lab and dry lab systems.
Disease-specific knowledge.
Clinical data access.
Longitudinal patient data.
Partnerships with hospitals or biobanks.
Automated experimentation.
Molecule libraries.
Target validation capabilities.
IP around discovered assets.
Regulatory-grade data generation.
Scientific team quality.
A company that owns a feedback loop between prediction and experiment may be stronger than a company that only runs models on public data.
This is why AI biotech founders must answer a hard question:
What do we know that others cannot easily know?
The answer cannot be “we use AI.”
Everyone uses AI.
The answer must be data, biology, workflow, experiments, assets, clinical insight, or execution.
6. Cell Therapy Has Already Proven Impact, but the Next Wave Must Solve Scalability
Cell therapy has already changed medicine, especially in hematologic cancers through CAR T-cell therapies.
McKinsey notes that cell therapies generated more than $3 billion in sales in 2022 and were projected to grow substantially by 2026. The category attracted more than $3 billion in VC funding in 2022.
The reason is obvious.
Cell therapy can do things traditional drugs cannot.
It can turn living cells into therapeutic systems.
It can engineer immune cells to recognize cancer.
It can potentially repair, regenerate, or modulate diseased tissue.
It can create highly targeted biological interventions.
But the field still has major challenges.
Autologous cell therapies, which use a patient’s own cells, are often complex, expensive, and slow to manufacture. They require collection, engineering, expansion, quality control, logistics, and reinfusion. That creates cost, time, and access barriers.
The next wave must improve:
Manufacturing.
Scalability.
Safety.
Persistence.
Specificity.
Solid tumor efficacy.
Off-the-shelf approaches.
Automation.
Treatment timelines.
Cost of goods.
Patient access.
Clinical workflow.
Allogeneic cell therapies, which use donor-derived or engineered cells that can be prepared in advance, are attractive because they may reduce time and cost. But they also create immunogenicity, persistence, rejection, and safety challenges.
Cell therapy is not only a biology problem.
It is a manufacturing and access problem.
A founder in this category must think about the factory as much as the cell.
7. Gene and Oligonucleotide Therapies Are Rewriting the Target Space
Gene and oligonucleotide therapies are powerful because they can intervene closer to the root of disease biology.
Instead of only modulating proteins after they are produced, these therapies can target DNA, RNA, or gene expression.
This includes:
Gene therapy.
Gene editing.
Base editing.
Prime editing.
mRNA.
siRNA.
antisense oligonucleotides.
RNA editing.
Transcriptome targeting.
Viral and nonviral delivery systems.
These approaches can open therapeutic possibilities in rare disease, oncology, immunology, metabolic disease, neurologic disease, and beyond.
McKinsey noted that VC investors provided about $3 billion in funding for gene and oligonucleotide therapies in 2022, and that startups were working on areas such as mRNA optimization, expanded gene editing, and transcriptome targeting.
The opportunity is enormous.
So are the challenges.
Delivery remains difficult.
Safety matters intensely.
Durability matters.
Immune response matters.
Manufacturing matters.
Regulation matters.
Pricing matters.
Long-term follow-up matters.
Rare disease markets may be clinically meaningful but commercially narrow.
A founder must be able to explain:
Why this modality fits this disease.
How the therapy reaches the right tissue.
How safety is controlled.
How durability is measured.
How manufacturing can scale.
How regulators will evaluate risk.
How pricing and access will work.
Gene and RNA therapies may be transformational, but the path to patients is demanding.
8. Immunology Has Become a More Attractive Asset-Based Area
McKinsey also notes a shift within asset-based biotech.
In 2022, immunology captured a larger share of asset-based funding, while oncology’s share declined compared with the prior year.
This does not mean oncology is unimportant. Oncology remains one of the largest and most scientifically active therapeutic areas.
But it does show that investors were looking for new areas of differentiated opportunity.
Immunology is attractive because immune biology underlies many diseases:
Autoimmune disease.
Inflammation.
Fibrosis.
Allergy.
Transplantation.
Gastrointestinal disease.
Dermatology.
Respiratory disease.
Rheumatology.
Neuroinflammation.
Investors are interested in immunology because large patient populations, chronic disease burden, validated commercial markets, and new mechanisms can create meaningful opportunities.
The rise of obesity and metabolic disease has also reshaped life-sciences investing more broadly. While McKinsey’s article focused on data through 2023, the later funding environment has shown how large therapeutic categories can draw investor attention when scientific breakthroughs, commercial scale, and pharma appetite converge.
The lesson is that asset-based biotech is still viable when the asset is differentiated and the market need is clear.
Not every biotech must be a platform company.
A focused drug with strong science, strong IP, clear biology, and a realistic development path can still be a major company.
9. Biotech Founders Must Understand Milestone-Based Value Creation
In software, founders often think in product, users, revenue, and growth.
In biotech, founders must think in risk reduction.
A biotech company becomes more valuable when it reduces uncertainty.
That uncertainty can be scientific.
Does the biology make sense?
Technical.
Can the molecule, cell, vector, or platform be built?
Preclinical.
Does it work in relevant models?
Manufacturing.
Can it be produced consistently?
Regulatory.
Can the company reach IND or equivalent filing?
Clinical.
Is it safe in humans?
Efficacy.
Does it produce a meaningful therapeutic effect?
Commercial.
Is the market large enough?
Reimbursement.
Will payers support it?
Each financing round should be tied to specific risk reduction.
A seed round may fund platform validation, early assays, IP, team building, or lead selection.
A Series A may fund preclinical proof, candidate nomination, IND-enabling studies, or early manufacturing.
A Series B may fund clinical entry, Phase 1 data, dose escalation, or biomarker evidence.
Later rounds may fund Phase 2 efficacy, expansion cohorts, manufacturing scale, or pivotal trial preparation.
The founder must know what the next milestone proves.
Not vaguely.
Specifically.
A biotech pitch should answer:
What risk does this round reduce?
What data will we generate?
Why does that data matter?
How will investors value the company after that milestone?
What happens if the data is mixed?
What is the backup plan?
Biotech investors do not fund time.
They fund risk reduction.
10. A Biotech Platform Must Eventually Become a Drug Company
Platform companies can be seductive.
They sound broad.
They promise multiple indications.
They attract large Series A rounds.
They can partner with pharma.
They can generate multiple assets.
But every platform company faces the same test:
Can it produce drugs?
A platform that never creates clinical assets is not enough.
A platform that produces interesting biology but no development path is not enough.
A platform that generates candidates but cannot prioritize them is not enough.
A platform that depends only on partnerships may struggle to capture full value.
A founder must decide when and how to become a product company.
There are several paths:
Build internal pipeline and retain ownership.
Partner early with pharma and use non-dilutive capital.
Develop one lead asset to clinical proof, then expand.
Use partnerships to validate the platform while funding internal programs.
Focus on rare disease first, then expand into larger indications.
Each path has tradeoffs.
Internal pipeline creates more upside but requires more capital.
Partnerships reduce cost but may give away economics.
Rare disease may offer clearer biology but smaller markets.
Large indications offer bigger potential but higher competition and trial cost.
A platform company must make strategic choices.
A platform is not a substitute for strategy.
11. Pharma Partnerships Are Often Essential, but Founders Must Be Careful
Biotech and pharma are deeply connected.
Large pharmaceutical companies need innovation to replenish pipelines, replace revenue lost to patent cliffs, expand therapeutic areas, and access new modalities.
Startups need capital, clinical development expertise, regulatory experience, manufacturing capacity, commercial infrastructure, and exit pathways.
This makes partnerships natural.
A startup may license a program.
Enter a discovery collaboration.
Create a co-development deal.
Sell an option.
Partner around a platform.
Use pharma funding to support non-dilutive development.
But founders must be careful.
A bad deal can limit future value.
A partnership can validate the company, but it can also restrict optionality.
Questions to ask:
Which rights are we giving away?
For which indication?
For which geography?
For which targets?
How much upfront cash is real?
What milestones are achievable?
Who controls development?
Who owns data?
Can we publish?
Can we develop adjacent programs?
Does the deal validate the platform?
Does it finance internal pipeline?
Does it make future fundraising easier or harder?
Founders should not partner because they are desperate.
They should partner because the deal accelerates the company.
The best partnerships combine capital, validation, expertise, and strategic freedom.
12. Public Markets Are Reopening Selectively, Not Generously
The biotech IPO market has shown signs of improvement in 2026, but it remains selective.
The strongest IPO candidates have usually been companies with more mature clinical assets, large prior venture funding, and programs in attractive therapeutic areas.
This matters for early-stage founders because the IPO market influences venture behavior.
When IPO markets are open, VCs can underwrite companies with clearer exit paths.
When IPO markets are closed, VCs become more dependent on M&A, private rounds, or partnerships.
A selective IPO market changes the standard.
Public investors may not reward preclinical platform companies as generously as they did during hotter markets.
They may prefer later-stage clinical assets.
They may want clearer human data.
They may want stronger balance sheets.
They may want tighter pipelines.
This does not mean early-stage platform companies cannot get funded.
It means they must understand how private investors imagine the eventual exit.
A founder should know:
Could this company go public?
At what stage?
With what data?
Could it be acquired?
By whom?
Could it partner first?
Could it raise crossover capital?
What would public investors need to believe?
Biotech founders should not obsess over exit too early, but they should understand the capital-market path.
13. M&A Is Not a Backup Plan. It Is Part of Biotech’s Operating System
In many technology sectors, acquisition can feel like one exit option among several.
In biotech, M&A is central.
Large pharma companies regularly acquire biotech startups to access assets, platforms, modalities, and pipelines.
This is not a weakness.
It is part of the industry structure.
Pharma has commercial infrastructure, global regulatory teams, clinical-development expertise, manufacturing capacity, and sales forces.
Startups often specialize in innovation, discovery, and early development.
The acquisition market allows innovation to move from startup labs into global development and commercialization.
But founders should not build only to be bought.
They should build a company that creates strategic value.
That value may come from:
A differentiated asset.
A validated platform.
A clinical proof point.
A modality advantage.
A manufacturing capability.
A data advantage.
A disease biology insight.
A pipeline.
A team.
The better the company, the more optionality it has.
A startup that must sell because it cannot raise capital has less leverage.
A startup that can raise, partner, or go public has more leverage.
Optionality is power.
14. Biotech Is a Team Sport Between Scientists, Operators, Clinicians, and Capital
A biotech startup cannot survive on scientific brilliance alone.
Science is necessary, but not sufficient.
The company also needs:
Drug development leadership.
Clinical strategy.
Regulatory expertise.
Manufacturing expertise.
IP counsel.
Finance.
Business development.
Translational medicine.
Biostatistics.
Commercial insight.
Patient access understanding.
Board governance.
Investor relations.
This is why experienced biotech company builders matter.
A founder coming from academia may understand the science deeply, but may need help turning the science into a company.
That help can come from:
Venture studios.
Entrepreneurs in residence.
Biotech VCs.
adMare-style company builders.
University translation offices.
Pharma veterans.
Experienced CEOs.
Clinical advisors.
Regulatory consultants.
Biotech is one of the clearest examples of why ecosystems matter.
The idea may start in a lab.
But the company requires a system.
15. Academic Science Must Cross the Translation Gap
Many biotech startups begin in universities or research hospitals.
That is a strength.
Academic science produces discoveries that can become medicines.
But the translation gap is real.
A discovery is not a company.
A paper is not a product.
A mechanism is not a drug.
A target is not a therapy.
A mouse model is not human proof.
A university spinout needs:
Clean IP.
Freedom to operate.
Founder incentives.
Company formation support.
Seed capital.
Translational funding.
Development plan.
Commercial leadership.
Access to labs.
Regulatory guidance.
Investor syndicate.
A poor university spinout process can kill good science.
Too much institutional control can discourage investors.
Unclear IP can delay fundraising.
Slow tech transfer can cause founders to lose momentum.
Europe and Canada both face this challenge. The USA does too, but its strongest biotech ecosystems have built deeper translation machinery around universities, hospitals, VCs, and pharma.
The future of biotech depends on turning more science into companies without trapping founders in institutional friction.
16. The USA Remains the World’s Biotech Capital Market
The USA is the strongest biotech startup market in the world.
It has:
Deep life-sciences venture capital.
Large pharma companies.
Top research universities.
Research hospitals.
FDA regulatory pathways.
Public markets.
Biotech-focused bankers.
Experienced boards.
Crossover investors.
Company-building VCs.
Strong hubs in Boston, San Francisco, San Diego, New York, North Carolina, Seattle, Philadelphia, Los Angeles, and other regions.
This creates a full-stack ecosystem.
A biotech founder in the USA can access specialized investors, experienced operators, pharma partners, clinical trial sites, regulatory advisors, public-market pathways, and acquisition buyers.
That does not mean the USA is easy.
Biotech in the USA is brutally competitive.
Costs are high.
Investors are selective.
Scientific bars are high.
Clinical development is expensive.
Public markets can punish weak stories.
But the ecosystem depth is unmatched.
This is why many global biotech startups seek U.S. investors, U.S. clinical strategy, U.S. regulatory pathways, or U.S. headquarters presence.
For founders outside the USA, the lesson is practical:
If your company is serious about global biotech, you must understand the U.S. capital and pharma ecosystem, even if you build elsewhere.
17. Canada Has World-Class Science, but Must Capture More Value
Canada has strong life-sciences research.
It has talent, universities, hospitals, AI expertise, immunology, oncology, regenerative medicine, RNA, cell therapy, biologics, clinical research networks, and important hubs in Toronto, Montreal, Vancouver, Ottawa, Calgary, Edmonton, and other centers.
But Canada’s challenge is scale and value capture.
Canadian science can create high-value companies, but domestic capital often becomes thinner as companies grow. Foreign investors, especially U.S. investors, frequently provide later-stage capital and capture much of the economic upside.
This is not automatically bad. International capital can be helpful. U.S. investors bring expertise, networks, pharma relationships, and scale capital.
But if Canada consistently derisks science domestically and then exports the upside, the ecosystem loses compounding power.
Canada needs:
More domestic life-sciences venture capital.
More growth-stage capital.
More pension and institutional participation.
More experienced biotech operators.
More domestic anchor companies.
More public-private translation funds.
More company-building infrastructure.
More pharma partnerships.
More commercialization support.
More strategic procurement and health-system pathways.
The question is not whether Canadian biotech can produce science.
It can.
The question is whether Canada can keep enough ownership, IP control, talent, and returns to fund the next generation.
18. Canada’s Biotech Founder Reality Is Different From the USA
Canadian biotech founders face a different operating environment.
They may have access to strong science, grants, research infrastructure, hospitals, and early-stage support.
But they may also face:
Smaller domestic funding pools.
Fewer large domestic specialist funds.
Less late-stage capital.
More dependence on U.S. investors.
Fewer local pharma headquarters.
Limited domestic acquisition market.
More pressure to relocate.
Slower commercialization pathways.
Fragmented provincial health systems.
Longer path to major global partnerships.
This means Canadian biotech founders must be strategic early.
They should ask:
Which proof can we build in Canada?
Which investors must we reach in the USA?
Which pharma partners are relevant globally?
Do we need a U.S. subsidiary?
Which clinical strategy supports FDA and Health Canada pathways?
Can Canadian non-dilutive funding reduce early risk?
How do we keep core IP and talent anchored?
Which Canadian investors can lead early?
Which international investors can scale later?
The best Canadian biotech founders will be proudly Canadian and globally fluent.
Local science.
Global capital.
Global clinical strategy.
Global pharma relevance.
19. Biotech Founders Should Not Confuse Grants With Product-Market Fit
Non-dilutive funding is important in biotech.
Grants can support early research, translational work, platform validation, preclinical studies, and lab infrastructure.
They can reduce dilution.
They can extend runway.
They can validate scientific promise.
But grants are not product-market fit.
A biotech company must eventually convince investors, pharma partners, regulators, clinicians, payers, and patients.
Grant funding can help reduce risk, but it should not define the company.
Founders should use grants to answer specific questions:
Can we validate the mechanism?
Can we generate animal data?
Can we support IND-enabling studies?
Can we improve the platform?
Can we build manufacturing readiness?
Can we develop biomarkers?
Can we strengthen IP?
The best use of non-dilutive capital is to make the next equity round or partnership more credible.
The worst use is to keep research alive without a company-building plan.
20. The Founder Must Know the Modality’s Business Model
Different biotech modalities require different strategies.
Small molecules.
Antibodies.
Cell therapies.
Gene therapies.
RNA therapies.
Radiopharmaceuticals.
Protein degraders.
Bispecifics.
Peptides.
Microbiome.
Synthetic biology.
Regenerative medicine.
AI-discovered assets.
Each has different timelines, manufacturing needs, regulatory risks, commercial models, and investor expectations.
For example:
A small-molecule company may need strong chemistry, target validation, and differentiation against existing drugs.
A cell-therapy company must think about manufacturing, safety, logistics, persistence, and access.
A gene-therapy company must think about delivery, durability, immunogenicity, and long-term follow-up.
An RNA company must think about tissue targeting, dosing, stability, delivery, and repeat administration.
An AI drug-discovery company must think about data, experimental validation, pipeline ownership, and pharma partnerships.
A radiopharmaceutical company must think about isotope supply, manufacturing, logistics, imaging, and specialized clinical sites.
Founders should not pitch biotech generically.
They should pitch the modality with its real-world development logic.
21. The Patient Must Stay in the Center of the Strategy
Biotech can become very abstract.
Platforms.
Modalities.
Targets.
Assays.
Models.
Financing rounds.
Licensing deals.
Valuations.
But the purpose is patients.
A strong biotech founder should be able to explain:
Which patients suffer from this disease?
What do current treatments fail to solve?
How severe is the unmet need?
How is the disease diagnosed?
Which clinicians treat it?
What endpoints matter?
What patient population is addressable?
What risks would patients accept?
What benefit would be meaningful?
How would access work?
How would payers evaluate value?
This patient-centered thinking improves strategy.
It helps choose indications.
It helps design trials.
It helps communicate with regulators.
It helps build commercial logic.
It helps investors understand why the company matters.
Biotech is not only about proving a mechanism.
It is about changing a patient outcome.
22. The Regulatory Path Is Part of the Product
Regulation is not an obstacle outside the business.
In biotech, regulation is part of the product path.
The founder must understand:
What agency pathway applies.
What preclinical data is required.
What toxicology package is needed.
What manufacturing controls matter.
What endpoints regulators may accept.
What safety signals must be monitored.
What patient population is appropriate.
What accelerated pathways may exist.
What companion diagnostics may be needed.
What long-term follow-up is required.
How the trial should be designed.
A biotech company that ignores regulation early may waste years.
A strong regulatory strategy can increase value because it gives investors confidence that the science can reach patients.
Regulatory strategy is not paperwork.
It is development strategy.
23. Manufacturing Is a Strategic Risk, Not a Back-Office Function
Many biotech companies underestimate manufacturing.
That is dangerous.
For small molecules, manufacturing may be relatively straightforward compared with advanced therapies, but quality, scale, cost, and supply still matter.
For biologics, cell therapies, gene therapies, RNA therapies, and radiopharmaceuticals, manufacturing can be one of the hardest parts of the company.
Manufacturing affects:
Clinical trial timelines.
Cost of goods.
Dose consistency.
Safety.
Regulatory approval.
Commercial access.
Scalability.
Supply reliability.
Gross margin.
A founder should not treat CMC as a late-stage problem.
CMC means chemistry, manufacturing, and controls. It is central to drug development.
Investors increasingly ask about manufacturability earlier because many advanced therapies struggle not only in biology, but in production and delivery.
A therapy that cannot be made consistently, affordably, and at scale may not become a medicine.
24. The Biotech Capital Stack Is Not Just Venture Equity
Biotech founders often think in venture rounds, but the capital stack can be broader.
Possible capital sources include:
Seed VC.
Series A/B/C venture capital.
Specialist life-sciences funds.
Crossover investors.
Corporate venture capital.
Pharma partnerships.
Licensing deals.
Research grants.
Disease foundations.
Government programs.
University translational funds.
Nonprofit capital.
Venture debt after sufficient maturity.
Public markets.
Strategic M&A.
Each source has a different role.
Grants can fund early research.
VC can fund company formation and risk reduction.
Disease foundations can support patient-driven areas.
Pharma partnerships can validate and fund programs.
Crossover investors can prepare the company for IPO.
Public markets can fund later-stage trials if open.
M&A can move assets into larger development organizations.
Founders should not use expensive equity for every risk if strategic or non-dilutive capital can reduce dilution.
But they should also avoid accepting partnership terms that give away too much too early.
Capital strategy is part of biotech strategy.
25. What Investors Should Look For in Early-Stage Biotech
Early-stage biotech investing requires specialized judgment.
Investors should evaluate:
Quality of science.
Strength of biological rationale.
Differentiation.
Modality fit.
IP position.
Founder and scientific team.
Translational plan.
Lead indication strategy.
Preclinical model relevance.
Manufacturing feasibility.
Regulatory path.
Clinical development plan.
Commercial opportunity.
Competition.
Platform breadth.
Capital required to next milestone.
Syndicate quality.
Exit optionality.
For AI biotech, investors should add:
Data uniqueness.
Experimental feedback loop.
Wet-lab integration.
Model validation.
Asset ownership.
Computational and biological team quality.
Proof that AI improves decisions.
For cell and gene therapies, investors should add:
Delivery.
Safety.
Manufacturing.
Durability.
Immunogenicity.
Cost.
Patient access.
Trial feasibility.
The most important question is:
What does this company know, prove, or build that others cannot easily replicate?
26. What Founders Should Learn From the 2023 to 2026 Market
The current biotech market teaches several lessons.
Public markets can reopen selectively, but not for everyone.
Large IPOs may happen, but the bar is high.
Clinical-stage companies have an advantage in public markets.
Platforms must show credible paths to assets.
AI must produce biological and clinical value, not only investor excitement.
M&A matters because pharma needs pipeline renewal.
Venture capital remains available, but investors are selective.
Down rounds and flat rounds are possible when milestones do not match valuation.
Capital efficiency matters, but underfunding can kill good science.
Biotech founders must build for multiple financing paths.
The easy-money era is not the right benchmark.
The right benchmark is disciplined risk reduction.
27. The Founder Playbook for Biotech Startups
Here is the practical founder playbook.
1. Define the first risk
What is the biggest uncertainty that must be reduced next?
2. Tie every round to a milestone
Do not raise for time. Raise to generate specific data.
3. Choose the lead program carefully
The lead program should prove the platform and support value creation.
4. Build the right team early
Science, development, regulatory, IP, manufacturing, and business development all matter.
5. Protect the IP
Clear IP is essential for fundraising and partnerships.
6. Understand the modality
Every therapeutic modality has different risks and development logic.
7. Plan manufacturing early
Especially for cell, gene, RNA, biologics, and radiopharmaceuticals.
8. Use AI with biological discipline
AI predictions must be validated experimentally and clinically.
9. Build pharma relationships before desperation
Partnerships work best when the company has leverage.
10. Keep patients central
The science must lead to meaningful clinical benefit.
11. Think globally
Biotech capital, pharma partnerships, and clinical development are global.
12. Preserve optionality
Build toward financing, partnership, M&A, or IPO paths where possible.
28. The Investor Playbook
For investors, early-stage biotech requires patience and discipline.
1. Do not chase platform language blindly
Ask how the platform becomes products.
2. Underwrite the next milestone
Know what data creates value.
3. Build strong syndicates
Biotech requires capital and expertise across stages.
4. Evaluate manufacturing early
Especially in advanced therapies.
5. Understand the exit environment
IPO, M&A, and partnership pathways shape financing.
6. Support founders with company-building
Academic founders often need operators.
7. Look beyond obvious hubs, but do not ignore ecosystem depth
Strong science exists everywhere, but company-building infrastructure matters.
8. Be careful with AI hype
AI must improve biology and development outcomes.
9. Think about pharma appetite
Large pharma needs pipeline renewal, but not every asset fits.
10. Fund patient impact, not only technology novelty
The ultimate value is clinical benefit.
29. What Canada Should Build
Canada should treat life sciences as a strategic sector.
That means building more than labs.
Canada needs:
More domestic life-sciences funds.
More specialist early-stage capital.
More growth-stage therapeutics capital.
More pension participation.
More company builders.
More biotech executives.
More translational infrastructure.
More pharma partnerships.
More commercialization-friendly university IP policies.
More cross-border clinical strategy.
More domestic anchor companies.
More reinvestment from exits.
The goal should not only be to create Canadian biotech startups.
The goal should be to create Canadian biotech companies that can scale globally while keeping meaningful value, IP, talent, and returns rooted in Canada.
Canada should not be satisfied with being a science supplier.
It should become a life-sciences company-building nation.
30. Conclusion: Early-Stage Biotech Investing Is a Map of the Future
McKinsey’s article shows that early-stage biotech investors did not stop believing in innovation when public markets became difficult.
They kept funding platforms.
Machine-learning-enabled drug discovery.
Cell therapies.
Gene and oligonucleotide therapies.
Immunology assets.
New biological approaches.
That is because early-stage biotech investing is not only a reaction to today’s market.
It is a map of what investors believe medicine could become.
The map is not guaranteed to be correct.
AI drug discovery may disappoint if it fails to improve clinical outcomes.
Cell therapy may remain constrained by manufacturing and cost.
Gene therapy may face delivery and safety challenges.
Platforms may struggle to become products.
Public markets may stay selective.
But the direction is clear.
Biotech innovation is moving toward more programmable, data-rich, engineered, precise, and platform-enabled medicine.
The winners will not be the companies with the broadest claims.
They will be the companies that generate the strongest evidence.
For founders, the lesson is discipline.
Build around milestones.
Reduce risk.
Choose indications wisely.
Protect IP.
Understand manufacturing.
Respect regulation.
Use AI practically.
Build pharma relationships.
Keep patients at the center.
For investors, the lesson is selective conviction.
Do not fund every platform story.
Fund the teams that can turn platforms into medicines.
For the USA, biotech remains one of the strongest areas of national innovation because the ecosystem combines capital, universities, hospitals, pharma, public markets, and experienced company builders.
For Canada, the opportunity is enormous, but the warning is clear: world-class science is not enough if too much of the economic upside leaves the country during scale-up and exit.
Biotech is difficult.
That is the point.
The companies that win can do more than create value for investors.
They can change what diseases are treatable.
That is why early-stage biotech investing matters.
It funds uncertainty today in the hope of changing medicine tomorrow.